- Home
- GORO vs SKYE Comparison
GORO vs SKYE Comparison
Compare GORO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- SKYE
- Stock Information
- Founded
- GORO 1998
- SKYE 2012
- Country
- GORO United States
- SKYE United States
- Employees
- GORO N/A
- SKYE N/A
- Industry
- GORO Precious Metals
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- SKYE Health Care
- Exchange
- GORO Nasdaq
- SKYE Nasdaq
- Market Cap
- GORO 133.7M
- SKYE 121.8M
- IPO Year
- GORO N/A
- SKYE N/A
- Fundamental
- Price
- GORO $0.92
- SKYE $1.38
- Analyst Decision
- GORO Strong Buy
- SKYE Strong Buy
- Analyst Count
- GORO 2
- SKYE 5
- Target Price
- GORO $1.38
- SKYE $14.75
- AVG Volume (30 Days)
- GORO 3.1M
- SKYE 1.8M
- Earning Date
- GORO 11-04-2025
- SKYE 11-06-2025
- Dividend Yield
- GORO N/A
- SKYE N/A
- EPS Growth
- GORO N/A
- SKYE N/A
- EPS
- GORO N/A
- SKYE N/A
- Revenue
- GORO $49,824,000.00
- SKYE N/A
- Revenue This Year
- GORO N/A
- SKYE N/A
- Revenue Next Year
- GORO $117.97
- SKYE N/A
- P/E Ratio
- GORO N/A
- SKYE N/A
- Revenue Growth
- GORO N/A
- SKYE N/A
- 52 Week Low
- GORO $0.12
- SKYE $1.14
- 52 Week High
- GORO $1.18
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- GORO 58.24
- SKYE 27.45
- Support Level
- GORO $0.78
- SKYE $1.50
- Resistance Level
- GORO $1.18
- SKYE $1.76
- Average True Range (ATR)
- GORO 0.09
- SKYE 0.24
- MACD
- GORO 0.01
- SKYE -0.18
- Stochastic Oscillator
- GORO 38.00
- SKYE 0.00
About GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.